Compare AdaptHealth Corp (AHCO) vs UiPath Inc (PATH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AdaptHealth Corp vs UiPath Inc — how do they compare? AdaptHealth Corp trades at $5.77 (market cap $753.09M), while UiPath Inc trades at $15.24 (market cap $8.14B). The key difference: UiPath Inc is far larger — about 10.8× AdaptHealth Corp's market cap, and UiPath Inc is trading nearer its 52-week high, AdaptHealth Corp nearer its low. Which is the better fit depends on your goals.
| AHCO | PATH | |
|---|---|---|
Market Cap | $753.09M | $8.14B |
Sector | Health | Technology |
52-Week High | $13.38 | $19.29 |
52-Week Low | $5.22 | $9.38 |
Enterprise Value | $2.77B | $6.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AdaptHealth (AHCO) trades at $5.63, up 7.85% today but remains under significant pressure after recent earnings disappointments. The stock shows bearish technical signals with oversold RSI readings, while fundamentals reveal negative profitability with a -6.82% net margin and three consecutive quarterly earnings misses. The company is restructuring by selling its diabetes unit to focus on sleep and respiratory care, but faces multiple securities fraud investigations following guidance revisions.
Despite 75% analyst buy ratings and an $11 consensus price target suggesting 95% upside, substantial risks exist including ongoing legal probes, execution challenges with new fixed-price contracts, and negative cash flow trends. The stock presents high-risk speculation amid operational restructuring and legal uncertainties.
UiPath (PATH) trades at $15.28, down 1.99% on the day, with a bullish technical signal from moving averages but bearish oscillators like RSI above 90. The company shows strong revenue growth, reaching $1.43 billion in 2025, and improving net income margins, though it remains unprofitable. Recent news highlights institutional buying and AI-driven stock rallies, with Q2 2026 earnings expected soon.
Outlook is mixed: PATH benefits from AI automation demand and profitability improvements, but high valuation ratios and earnings volatility pose risks. Analysts are cautious with a consensus price target of $13.33, below the current price, suggesting limited upside amid competitive and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AdaptHealth Corp
AdaptHealth provides patient-centered healthcare-at-home solutions in the U.S. It offers medical equipment and supplies for sleep therapy, respiratory health, diabetes management, and general home wellness.
Read more on AHCO →About UiPath Inc
UiPath Inc creates an end-to-end platform that provides automation with user emulation at its core. Its platform is built to be used by employees throughout a company and to address a wide variety of use cases, from simple tasks to long-running, complex business processes. It generates revenue from the sale of licenses for its proprietary software, maintenance and support, and professional services. It generates a majority of the revenues from the US, followed by Romania and the rest of the world.
Read more on PATH →
